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Self-assembling block copolypeptides were prepared by sequential ring-opening 
polymerization of N-carboxyanhydride (NCA) derivatives of γ-benzyl-L-glutamic acid and ε-
carbobenzyloxy-L-lysine, followed by selective deprotection of the benzyl glutamate block.  
The synthesized polymers had number average molecular weights close to theoretical values, 
and had low dispersities (ƉM = 1.15-1.28).   Self-assembly of the amphiphilic block 
copolymers into nanoparticles was achieved using the ‘solvent-switch’ method, whereby the 
polymer was dissolved in THF and water and the organic solvent removed by rotary 
evaporation.  The type of nanostructures formed varied from spherical micelles to a mixture 
of spherical and worm-like micelles, depending on copolymer composition.  The spherical 
micelles had an average diameter of 43 nm by dynamic light scattering, while the apparent 
diameter of the mixed phase system around 200 nm.  Reproducibility of nanoparticle 
preparation was demonstrated to be excellent; almost identical DLS traces were obtained over 
three repeats.  Following qualitative dye-solubilisation experiments, the nanoparticles were 
loaded with the ocular anti-inflammatory drug dexamethasone.  Loading efficiency of the 
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nanoparticles was 90% and the cumulative drug release was 94% over 16 days, with a 20% 
burst release in the first 24 hours. 
 
FIGURE FOR ToC_ABSTRACT 
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1. Introduction 
Disorders affecting the posterior segment of the eye, which cause visual impairment and 
blindness, are occurring at an increasing rate[1].  For example, it has been estimated that 
within a few years ca. 30 million Americans will be affected by age-related macular 
degeneration (AMD).  Injection of drugs into the vitreous cavity (intravitreal injection) 
delivers therapeutics to the target site, however, when the disease is chronic, such as with 
uveitis, macular edema and AMD, frequent injections are required to achieve intraocular drug 
levels within the therapeutic range.  This can cause severe secondary effects such as cataracts, 
retinal detachment, endophthalmitis and intravitreal haemorrhages.  Even though intravitreal 
injection is accepted clinically, patient compliance is poor and the risk of complications 
increases dramatically as the number of required injections increases with the age of the 
patient.  An effective drug delivery platform is required to solve this problem. 
 
Currently, micro- and nanoparticles prepared from linear, biodegradable polyesters such as 
poly(lactic-co-glycolic acid) (PLGA) are used as intraocular drug delivery systems.[2] 
However, polymer degradation produces acidic species that can cause inflammation. In 
addition, chemical functionalisation of the particle surface is non-trivial and drug release 
cannot be triggered.  Self-assembling peptide-based materials have a number of attractive 
features in the context of nanoparticles for drug delivery[3]: their biodegradation produces 
non-inflammatory amino acids; rich chemical diversity allows easy attachment of, inter alia, 
targeting vectors and species to improve biocompatibility; self-assembly in aqueous media is 
compatible with the loading of sensitive cargoes such as growth factors, proteins, 
biopharmaceuticals and nucleotides. 
 
An efficient method for preparing self-assembling polypeptides is by the polymerisation of N-
carboxyanhydride (NCA) derivatives of a-amino acids[3-5].  Controlled polymerisation of 
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NCAs to produce well-defined polypeptides of desired molecular weight and narrow 
dispersity can be achieved using a variety of species including primary amines[6], certain 
transition metal complexes[7, 8] and N-trimethylsilylamines[9, 10].  When using primary amines 
as initiators, a number of strategies to improve polymerisation control, including lower 
reaction temperatures[11, 12], the use of ammonium salts as dormant initiators[13, 14] and the 
removal of CO2 by purging the reaction vessel with inert gas[15], have been employed.  In our 
work, we use TMS-amines developed by Cheng et al.[9, 10] as initiators, since polymerisations 
are generally more rapid and give better control than when primary amines are used.  Here we 
report the preparation of nanoparticles from block copolymers of poly(L-glutamic acid) and 
poly(ε-carbobenzyloxy-L-lysine), synthesised by sequential NCA polymerization of benzyl-
L-glutamate (BnE) and Z-lysine (ZK) NCAs, followed by deprotection of the benzyl-L-
glutamate block (Figure 1).  We chose to deprotect the BnE rather than the ZK block since 
poly(L-lysine) is known to be cytotoxic. Poly(glutamic acid-b-lysine) block copolymers have 
been prepared previously from NCA polymerization by Lecommandoux et al. and were 
shown to assemble into a variety of nanostructures[16, 17], but only at low (<4) or high (>10) 
pH values which are not suitable for drug delivery applications. 
 
 
Figure 1. Synthesis of amphiphilic poly(L-glutamic acid)-b-(ε-carbobenzyloxy-L-lysine). 
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2. Experimental Section 
2.1. Materials and Instrumentation 
H-Glu(Bn)-OH and H-Lys(Z)-OH were purchased from Novabiochem. Alpha-pinene was 
purchased from Sigma Aldrich. Triphosgene was purchased from Alfa Aesar.  N-
Benzyltrimethylsilylamine was purchased from TCI. Dexamethasone ≥ 98% was obtained 
from Sigma-Aldrich. Acetonitrile (ACN; HPLC grade), dichloromethane (DCM; laboratory 
grade) and phosphate buffered saline (PBS) were obtained from Fisher Scientific and distilled 
H2O from a high purity source. PBS was obtained in the form of tablets: one tablet is to 
dissolve in 100 ml dist. H2O (one tablet consists of 137 mM NaCl, 10 mM phosphate, 2.7 mM 
KCl and pH 7.3-7.5).  DMF (anhydrous) was purchased from Sigma Aldrich. THF was 
purchased from Fischer Scientific and dried by passage through two alumina columns using 
an Innovative Technology Inc. solvent purification system and stored under nitrogen. THF 
was further dried over sodium/ benzophenone complex with at least 3 freeze thaw cycles until 
the purple colouration persisted.  Float-A-Lyzer® dialysis cassettes (MWCO 20 kDa; size: 1 
ml) were obtained from Sigma-Aldrich Cronus and nylon 0.45 µm filters and Millex MP 0.22 
µm filters were obtained from Fisher Scientific.  NMR spectra were recorded using a Varian 
Inova 500 spectrometer at 499.87 (1H), a Varian VNMR-700 spectrometer at 699.73 MHz and 
a Bruker Advance 400 spectrometer at 400.13 MHz (1H) or 100.26 (13C).  NMR spectra were 
analyzed using MestRE Nova 6.2 software.  Gel permeation chromatography was undertaken 
with THF and DMF as solvents. 100 µL of solution agitated overnight to ensure complete 
dissolution was injected at a flow rate of 1.00 ml min-1 by a Viscotek SEC autochanger model.  
A Viscotek TDA 301 unit with triple detection (right angle laser scattering at 670 nm, 
differential refractometer and viscometer) was used.  Analyses were undertaken using 
OmniSEC 4.0 software.  Dynamic light scattering was conducted on a Brookhaven ZetaPlus 
combined DLS and zeta potential analyzer.  Particle size was determined using BIC Particle 
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sizing software.  TEM was carried out using an Hitachi H-7600 operating at 100 kV, the TEM 
camera system was operated using AMT 600 software.  One drop (10 ml) of prepared 
aggregate solution was placed on a glow discharged (20 seconds), carbon coated, 400 mesh 
copper grid for 30 seconds, blotted with filter paper and stained with 1% aqueous uranyl 
acetate for 30 seconds. Nanoparticles were prepared using a Büchi Rotavapor R-215 
consisting of a Vacuum controller V-855 and Heating bath B-491.  Dexamethasone loading 
and release were determined by HPLC using a Perkin Elmer HPLC Series 200 with a pump 
(Perkin Elmer series 200), a UV/VIS detector (Perkin Elmer series 200), a vacuum degasser 
(Perkin Elmer series 200), an auto sampler (Perkin Elmer series 200) and Total Chrom 6.3.1 
HPLC Software. The chromatographic separation was achieved with a C18 column Tracer 
Excel 120 ODSA (particle size 5 µm, 150 mm x 4mm; Teknokroma S. Coop., Barcelona, 
Spain). 
2.2. Synthesis of γ-Benzyl-L-glutamic acid (BnE) NCA 
 
To a stirred suspension of H-Glu(Bn)-OH (2.00 g, 8.43 mmol) in 20 mL of anhydrous THF 
under an atmosphere of nitrogen at 50 °C was added triphosgene (0.84 g, 2.81 mmol) in one 
portion and stirred to dissolution. The reaction was stirred under a flow of nitrogen for 3 h at 
50 °C. When solid starting material remained after one hour, an aliquot (0.05 equiv.) of 
triphosgene was added and this was repeated every half an hour if there was still solid left. 
After this time the reaction mixture was allowed to cool down to room temperature. The 
reaction mixture was added to ice-cold (-18 °C) hexane (60 mL) and the precipitate 
recrystallized twice from THF/hexane at -18 °C. The white solid was obtained by 
centrifugation following each crystallization, and finally dried under high vacuum overnight 
to afford BnE NCA (1.62 g; 73% yield) as a white powder. 1H NMR (500 MHz, CDCl3, δ) 
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7.36 (m, 5H, H9), 6.26 (s, 1H, H2), 5.14 (s, 2H, H8), 4.37 (m, 1H, H3), 2.61 (t, J = 6.5 Hz, 2H; 
H6), 2.29 (m, 1H, H5a), 2.13 (m, 1H, H5b). 13C NMR (125 MHz, 1H-decoupled, CDCl3, δ): 
172.3 (C7), 169.1 (C4), 151.2 (C1), 134.9 (C9), 128.6 (C9), 128.5 (C9), 128.2 (C9), 67.0 (C8), 
56.9 (C3), 29.9 (C6), 26.8 (C5). IR (film): ν = 3327, 1855 (C=O amide), 1774 (C=O 
anhydride), 1715 (C=O ester), 1241, 1194, 1104, 937, 735, 618 cm-1. 
 
2.3. Synthesis of ε-Carbobenzyloxy-L-Lysine (ZK) NCA 
 
 
To a stirred suspension of H-Lys(Z)-OH (2.00 g, 7.13 mmol) in 20 mL of anhydrous THF 
under an atmosphere of nitrogen at 50 °C was added triphosgene (0.71 g, 2.38 mmol) in one 
portion and stirred to dissolution. The reaction was stirred under a flow of nitrogen for 3 h at 
50 °C. When solid starting material remained after one hour, an aliquot (0.05 equiv.) of 
triphosgene was added and this was repeated every half an hour if there was still solid left. 
After this time the reaction mixture was allowed to cool down to room temperature. The 
reaction mixture was added to ice-cold (-18 °C) hexane (60 mL) and the precipitate 
recrystallized twice from THF/hexane at -18 °C. The white solid was obtained by 
centrifugation following each crystallization, and finally dried under high vacuum overnight 
to afford ZK NCA (2.02 g; 93% yield) as a white powder. 1H NMR (500 MHz, CDCl3, δ): 
7.36 (m, 5H, H12), 6.64 (s, 1H, H2), 5.11 (s, 2H, H11), 4.89 (s, 1H, H9), 4.28 (s, 1H, H3), 3.20 
(m, 2H, H8), 1.99 (m, 1H, H5a), 1.82 (m, 1H, H5b), 1.56 (m, 4H, H6,7). 13C NMR (125 MHz, 
1H-decoupled, CDCl3, δ): 168.8 (C4), 156.0 (C10), 151.2 (C1), 135.3 (C12), 127.6 (C12), 127.3 
(C12), 127.1 (C12), 66.0 (C11), 56.4 (C3), 38.9 (C8), 29.6 (C5), 28.1 (C7), 20.0 (C6). IR (film): ν 
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= 3335, 1852 (C=O amide), 1804 (C=O anhydride), 1766 (C=O ester), 1680, 1248, 1136, 941, 
750, 688 cm-1. 
 
2.4. Synthesis of Poly(γ-benzyl-L-glutamic acid) (PBnE) 
 
γ-Benzyl-protected L-glutamic acid NCA (0.5 g, 1.89 mmol) was dissolved in anhydrous 
DMF (10 ml). A Schlenk tube was preflushed with nitrogen gas before the dissolved NCA 
compound was added. N-Benzylamine TMS (0.038 mmol) was added dropwise to the 
Schlenk tube. The reaction was stirred for 24 hours at room temperature. To stop the reaction, 
the solution was added dropwise to diethyl ether (190 ml). The product was stored overnight 
at -8 ˚C for precipitation. After complete precipitation the sample was centrifuged to obtain a 
white solid. Further purification was carried out by re-dissolving in THF following by 
precipitation in 20-fold excess of diethyl ether. The purification was repeated one further 
time. The final pure product was dried under high vaccum overnight to obtain a white powder 
(0.551 g, 66% yield).  1H NMR (400 MHz, CDCl3, δ):  8.33 (1H, H6), 7.26 (5H, H5), 5.04 
(2H, H4), 3.94 (1H, H1), 2.58 (2H, H3), 2.29 (1H, H2b), 2.13 (1H, H2a). IR: ν = 3298, 3034 
(aromatic ring), 2960, 1730 (C=O carboxylic ester), 1650 (C=O ketone), 1544, 1452, 1164 
(C-O carboxylic ester), 976, 742, 696, 610, 508 cm-1. GPC (THF): Mn 11,100; ƉM 1.15. 
 
2.5. Synthesis of γ-Benzyl-L-glutamate / ε-Carbobenzyloxy-L-lysine Block 
Copolymers (PBnE-b-ZK) 
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Block copolypeptides were prepared by sequential monomer addition without intermediate 
purification steps. Different target molecular weights and block ratios were obtained by 
varying the monomer to (macro)initiator ratio.  The following aims to produce the block 
copolymer PBnE30-b-ZK30 and serves as a general procedure: BnE NCA (100 mg, 0.38 mmol) 
was dissolved in 1.5 mL of dry DMF, and injected into a Schlenk tube fitted with a Young’s 
tap and 9mm rubber septum pre-filled with nitrogen. N-Benzyltrimethylsilylamine in DMF 
(127 µL, 0.1M, 0.0127 mmol) was added via syringe into the tube and allowed to stir for 24 h. 
Following this a 30 µL sample was withdrawn and diluted to give a 1 mg/mL solution for 
GPC analysis. ZK NCA (137 mg, 0.38 mmol) was dissolved in 1.5 mL of dry DMF, and via 
syringe added to the reaction mixture. After 24 h of additional stirring a 30 µL sample was 
withdrawn and diluted to give a 1 mg/mL solution for GPC analysis and the remainder of the 
reaction was poured into a 20-fold excess of diethyl ether with stirring. The precipitated solid 
was collected by centrifugation. Further purification was achieved by re-dissolving in THF 
and precipitating into a 20-fold excess of diethyl ether to afford the block copolypeptide 
(yield 184 mg, 91%) as a white powder. 1H NMR (500 MHz, CDCl3, δ): 8.10-8.50 (m, 2H, 
H1,7), 7.10-7.40 (m, 10H, H6,15), 5.50 (m, 1H, H13), 4.90-5.20 (m, 4H, H5,14), 3.80-4.00 (m, 
2H, H2,8), 3.00-3.20 (m, 2H, H12), 1.80-2.70 (m, 4H, H3,4), 1.30-1.70 (m, 6H, H9,10,11). GPC 
(DMF): Mn 15,800; ƉM 1.17. 
 
2.6. Deprotection of Poly(γ-benzyl-L-glutamate)-b-(ε-carbobenzyloxy-L-lysine) 
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The block copolymers were dissolved in THF (0.025 g ml-1). Potassium hydroxide (1.5 mol 
equivalent per benzyl ester function) was dissolved in a minimum of H2O and added to the 
reaction mixture. The reaction was stirred for 15 hours before it was added dropwise to an 
excess of diethyl ether. The product precipitated and it was stored for 1 hour at -8 ˚C. The 
mixture was centrifuged and the supernatant was removed. A further washing step was carried 
out before the product was obtained as a white powder (46% yield for PE50-b-ZK25, 66% yield 
for PE50-b-ZK50). 
1H NMR of PE50-b-ZK25 (400 MHz, D2O, δ): 4.34 (1H, H1), 2.26 (2H, H3), 1.84 – 2.15 (2H, 
H2). 
1H NMR of PE50-b-ZK50 (400 MHz, D2O, δ): 4.30 (1H, H1), 2.23 (2H, H3), 1.81 – 2.14 (2H, 
H2). 
 
2.7. Self-assembly 
The polymers were first dissolved in THF at a concentration of 1.0 mg ml-1. Filtered MilliQ 
water was added to the solution and it was stirred overnight, allowing the THF to evaporate. If 
necessary, the solutions were finally filtered through a 0.45 µm filter. The final polymer 
concentration in water was 1.0 mg ml-1. 
 
2.8. Nile Red encapsulation 
H
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Polymers were dissolved in a solution of 0.02 mg ml-1 of Nile Red in THF resulting in a 
dissolved polymer concentration of 1.0 mg ml-1. After successful dissolution, filtered MilliQ 
water was added and it was stirred overnight to allow the THF to evaporate. The final 
polymer concentration in water was 1.0 mg ml-1. 
 
2.9. Dexamethasone Encapsulation and Release 
The nanoparticles loaded with dexamethasone (DX) were prepared following this procedure: 
10 mg of the polymer were dissolved in 5 ml solution of 0.1 mg ml-1 DX in THF and 5 ml 
dist. H2O was added. First the solution was vortexed for 30-60 s and then was sonicated for a 
further 5-15 min depending on the solubility. The solution was condensed under reduced 
pressure using a Büchi rotary evaporator with the following settings: 15 min at 200 mbar 
pressure (Δ pressure 5 mbar), rotation 150 rpm and water bath at 23 °C, then a further 15 min 
at 100 mbar pressure (Δ pressure 5 mbar), rotation 150 rpm and water bath at 23 °C. The 
nanoparticles were filtered with a 0.22 µm Millex MP, pipetted into an Eppendorf tube and 
then lyophilised overnight. 1 mg of the lyophilised nanoparticles were resuspended in 1 ml of 
a filtered PBS solution (with a Cronus and nylon 0.45 µm) and further characterized (TEM 
and DLS) and used for the DX release. The DX loaded nanoparticles (1 ml) were pipetted into 
a pre-treated dialysis cassette (washed first with 10% isopropanol then dist. H2O and finally 
with filtered PBS) and enclosed by 30 ml of filtered PBS in a falcon tube and incubated under 
gentle agitation at 37 °C. At different time points (1 h, 3 h, 5 h, 7 h, 24 h, 48 h, 4 d, 6d, 8 d, 10 
d, 12 d, 14d and 16), a 10 ml sample of the PBS was taken and replaced with freshly filtered 
PBS and further analysed by HPLC with UV detection at 254 nm. For analysis of the DX 
encapsulation efficiency 5 mg of nanoparticles were dissolved in 200 µl DCM and then 800 
µl of ACN were added and after strong vortexing for 2 minutes the solution was centrifuged 
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at 13,000 rpm for 20 min. Thereafter the supernatant was removed, filtered through a Millex 
MP 0.22 µm filter and analysed analysed by HPLC with UV detection at 254 nm.   
 
The composition of the mobile phase A was acetonitrile:water (35:65 v/v). The mobile phase 
B was composed by 100% acetonitrile.  Gradient elution method: 
Step min (duration) A % B% slope 
0 1 100 0  
1 10 100 0  
2 5 0 100 1 
3 5 100 0 1 
4 5 100 0  
5 1 100 0  
 
The mobile phase flow was set at 1 ml min-1 and the injection volume was 150 µl. After 
equilibration with the solvent to obtain a stable baseline, aliquots of samples were injected. 
The absorbance of the eluent was monitored at 254 nm with a detection sensitivity of 0.10 
aufs. All analyses were performed at 25ºC.  
 
For analysis of DX encapsulation efficiency, stock solutions of DX were prepared by 
dissolving 5 mg of DX in 25 ml in DCM:ACN (2:8) (0.2 mg ml-1). Solutions were protected 
from exposure to light. The resulting solutions were then diluted with DCM:ACN (2:8)  to 
give drug concentrations of 2 µg ml-1, 5 µg ml-1, 10 µg ml-1, 15 µg ml-1 and 20 µg ml-1.  For 
analysis of DX release, stock solutions of DX were prepared by dissolving 5 mg of DX in 25 
ml of PBS (0.2 mg ml-1). Solutions were protected from exposure to light. The resulting 
solutions were then diluted with PBS to give drug concentrations of 2 µg ml-1, 5 µg ml-1, 10 
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µg ml-1, 15 µg ml-1 and 20 µg ml-1.  The assay was validated with respect to linearity, 
accuracy and reliability in the range of concentrations of 2-20 µg ml-1. 
 
Encapsulation efficiency was calculated via following equation: 
Actual drug loadingDrug encapsulation efficiency (%, w/w)= 100
Theoretical drug loading
×
 
The drug loading of drug was calculated by the following equation: 
Actual drug loadingDrug loading (%, w/w)= 100
overall mass of NPs
×
 
 
3. Results and Discussion 
For the synthesis of amphiphilic polymers, a hydrophilic and a hydrophobic monomer is 
required.  We decided to use γ-benzyl-protected L-glutamic acid (BnE) and ε-
(benzyloxycarbonyl)-L-lysine (ZK) as the parent amino acids.  Although these monomers will 
initially form hydrophobic diblock copolymers, either amino acid can be deprotected to 
produce an amphiphilic block copolymer product.  Triphosgene is the most widely used 
compound to create N-carboxyanhydride (NCA) derivatives for ring-opening polymerisation 
(ROP). In this work, the procedure according to Daly and co-workers was followed[18].  After 
two hours reaction time in THF, full conversion of the amino acids into NCAs was observed.  
All reaction mixtures became clear solutions and the products were recrystallized several 
times to remove the by-product, HCl. As a consequence, yields of these NCAs were high 
using the exact conditions as described by Daly and co-workers. 
 
Homopolymerization of BnE NCA was carried out using TMS-protected benzylamine as 
initiator, giving a high degree of control over the reaction.  The predicted number average 
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molecular weight (Mn) agrees very well with the observed value and the low dispersity value 
(ƉM = 1.15) indicates a controlled polymerization (Table 1).  Therefore, block 
copolymerizations were also carried out using this initiator.  It was found that isolation and 
purification of the first BnE block before attempting chain extension with ZK NCA did not 
lead to well-defined block copolymers (data not shown).  Consequently, the ZK NCA was 
added directly to the reaction medium after complete consumption of the BnE NCA.  In this 
manner, block copolypeptides with either a 1:1 or 2:1 target block ratio between BnE and ZK 
were synthesized successfully.  Before the addition of ZK NCA a small sample was removed 
for GPC analysis, to investigate the control of the polymerization of the first block. 
Determination of the poly-Z-protected lysine (PZK) block length was carried out by NMR-
peak integration measurements. All block copolymers showed good to excellent control over 
the polymerization. The ƉM values ranged from 1.12 to 1.28 for polymers with a ratio of 2:1 
and the polymer with a ratio of 1:1 showed a low PDI of 1.27. 
 
Table 1. Characterisation Data for Poly(γ-benzyl-L-glutamic acid)-b-(ε-carbobenzyloxy-L-
lysine) Copolymers 
Sample Expected Mn [Da] 
Obtained 
Mn [Da] 
ƉM 
Block ratio 
(E:K)a) 
Yield [%] 
PBnE50 11,057 11,100 1.15 n/a 66 
PBnE30-b-
ZK30 
14,700 15,800b) 1.17 49:51 91 
PBnE30-b-
ZK15 
10,607 14,500b) 1.17 60:40 88 
PBnE50-b-
ZK50 
24,157 30,500c) 1.27 50:50 68 
PBnE50-b-
ZK25 
17,607 20,400c) 1.28 71:29 72 
 
a) determined by 1H NMR spectroscopy; b) determined by GPC using DMF as eluent; c) Mn of 
first block determined by GPC (THF eluent); total Mn estimated by GPC and 1H NMR 
spectroscopy. 
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Block copolypeptide products were converted into amphiphilic polypeptides by hydrolysis of 
the benzyl protecting group on the glutamate block. This strategy was favoured over the 
alternative lysine side-chain deprotection route since polylysine is known to be cytotoxic[19].  
Cleavage of the benzyl protecting group was achieved under basic conditions using 1.5 
equivalents of potassium hydroxide in THF per benzyl ester function[20]. After two 
precipitation steps in diethyl ether and drying under high vacuum, the amphiphilic block 
copolypeptide product was analyzed by 1H-NMR spectroscopy in D2O. Since the amphiphilic 
product self-assembles in this medium, it was suggested that the deprotected poly(glutamic 
acid) (PGA) block would be seen in the spectrum. Indeed, a nearly complete absence of 
aromatic peaks was observed (Figure 2). This indicates that the aromatic rings of 
carbobenzyloxy protecting groups may be located in the core of micelles and therefore cannot 
be detected by the magnetic field. 1H-NMR measurements in DMSO permit the analysis of 
both blocks and confirmed the presence of carbobenzylic protecting groups. Further analysis 
of integral ratios showed that the present aromatic peaks belong only to the carbobenzylic 
group resulting in the formation of amphiphilic PGA-b-PZK block-copolymers. 
 
Figure 2. 1H NMR spectrum of poly(L-glutamic acid)-b-(ε-carbobenzyloxy-L-lysine) in D2O 
following deprotection of the glutamate block with KOH. 
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Table 2. Data for Poly(L-glutamic acid)-b-(ε-carbobenzyloxy-L-lysine) Copolymer Self-
assembly 
Sample 
Particle 
diameter 
[nm] 
Zeta 
potential 
[mV] 
CMC [g 
ml-1] 
PE50-b-ZK25 207 -155 1x10-3 
PE50-b-ZK50 43 -155 1x10-2 
 
The solvent evaporation method was used to obtain self-assembled nanoparticles from PE-b-
ZK block copolymers. The polymer was dissolved in THF and the same volume of water was 
added, followed by evaporation of the THF overnight. In all measurements, 1 mg ml-1 
polymer concentration was used to create nanoparticles.  Both block copolypeptides, PE50-b-
ZK25 and PE50-b-ZK50 were self-assembled in this manner, and the diameter of the 
nanoparticles as determined by dynamic light scattering were found to be 207 nm and 43 nm, 
respectively (Table 2; Figure 3D).  DLS measurements do not provide information about the 
morphology of the assembled particles, therefore TEM images were also obtained (Figure 3).  
Sample PE50-b-ZK25 shows the presence of both spherical and worm-like particles (Figure 
3A).  The spherical particles have a diameter of around 30 nm, whereas the worm-like 
structures are much larger.  PE50-b-ZK50 also shows both spheres and worms, but appears 
more homogeneous with fewer worm-like structures (Figure 3B).  This could explain the 
difference in DLS diameter between the two samples.  PE50-b-ZK25 has a larger apparent 
diameter by DLS due to the greater number of large, worm-like structures.  Both sets of 
particles further showed a zeta potential of -155 mV that indicates the presence of the 
hydrophilic unprotected PGA block at the outer surface of the particles.  
 
Due to their morphology and size, these nanoparticles may be suitable for drug delivery 
applications. Therefore, encapsulation of the hydrophobic dye Nile Red as a model ‘drug’ was 
investigated (Figure 3D).  After Nile Red was dissolved in THF, the same amount of 
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polypeptide was added.  Water was added after complete dissolution of the polypeptide and 
the THF was evaporated, causing the polypeptide to self-assemble and forcing the 
hydrophobic dye into the cores of the self-assembled nanostructure.  The encapsulated dye 
turns the solution from hazy white into an almost clear light purple solution, indicating 
successful self-assembly and encapsulation. Interestingly, the size of particles is reduced 
significantly in the presence of the hydrophobic dye. Nile Red encapsulated samples showed a 
diameter reduction of 50% or more. It is suggested that the hydrophobic dye forces 
hydrophobic ends of the polypeptides into the core, thereby shrinking the size of the particles. 
 
 
Figure 3. Self-assembly of PE-b-ZK copolymers: a) TEM of PE50-b-ZK25; b) TEM of PE50-b-
ZK50; c) encapsulation of Nile Red by self-assembled nanostructures from PE50-b-ZK50 (left – 
A 
C 
B 
D 
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without Nile Red; right – with Nile Red); d) DLS data for self-assembled nanostructures from 
PE50-b-ZK25. 
 
Following successful encapsulation of Nile Red, we next explored the encapsulation and 
release of the anti-inflammatory ocular drug dexamethasone (DX).  Nanoparticles from PE50-
b-ZK25 were prepared in the presence of DX (polymer:DX = 1:0.75) by the solvent 
evaporation approach using a controlled method involving defined periods of reduced 
pressure and temperature.  The resulting nanoparticles were filtered to remove any large ill-
defined aggregates, isolated by freeze-drying and resuspended in buffer.  Repeated 
preparation of the DX-loaded nanoparticles showed excellent reproducibility, giving an 
average particle diameter of around 180 nm (Figure 4).  The release of DX through a dialysis 
membrane was then monitored at 37 oC over 16 days (polymer:Dx = 20:1).  Prior to release, a 
small portion of the loaded nanoparticles was precipitated into acetonitrile and the DX loading 
was determined by HPLC, giving a drug loading of 5.5 wt% and a loading efficiency of 90%.  
The release profile is shown in Figure 5.  Around 20% burst release of dexamethasone is 
observed in the first 24 hours, after which the release is steady over the remaining period of 
the study.  After 16 days, 94% of the loaded dexamethasone had been released. 
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Figure 4. DLS traces of 3 repeat preparations of nanoparticles from PE50-b-ZK25 (polymer 
concentration 1 mg/ml) loaded with dexamethasone (0.75 mg ml-1). 
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Figure 5. Release of dexamethasone from PE50-b-ZK25 nanoparticles. 
 
4. Conclusions 
Well-defined amphiphilic block copolypeptides were prepared by sequential NCA ring-
opening polymerization and were shown to self-assemble into nanoparticles in aqueous 
solution at pH 7.  The nanoparticle morphology was dependent on composition: spherical 
micelles were found in the case of the PE50-b-ZK50 polymer, whereas a mixture of spherical 
and worm-like micelles was found with the polymer PE50-b-ZK25.  A protocol for 
nanoparticle preparation was developed, giving reproducible nanoparticles with a consistent 
diameter over three repeats.  Successful encapsulation of the dye Nile Red demonstrated the 
ability of the nanoparticles to be loaded with hydrophobic molecules.  Consequently, the 
loading and release of the hydrophobic ocular drug dexamethasone was investigated.  The 
drug could be loaded with 90% efficiency at 5.5% of total nanoparticle mass, and 94% of the 
drug was released over 16 days in aqueous medium at 37 oC.  These results demonstrate the 
potential for self-assembled block copolypeptides to act as nanoscale drug delivery vehicles 
for application in the eye. 
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Nanoparticles from amphiphilic block copolypeptides are loaded with the ocular drug 
dexamethasone.  The block copolypeptides are synthesized by sequential polymerization of 
benzyl-protected glutamic acid and Z-protected lysine N-carboxyanhydrides (NCAs).  
Selective deprotection of the benzyl glutamate block yields amphiphilic block copolymers 
that self-assemble into nanoaprticles in aqueous solution.  Drug release is almost complete 
after 16 days in aqueous solution at 37 oC. 
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